No Impact of Resistance Associated Substitutions on the Efficacy of Sofosbuvir, Velpatasvir, and Voxilaprevir for 12 Weeks in HCV DAA-experienced Patients

Chronic hepatitis C virus infection (HCV) is a global health problem causing death and morbidity [1]. Recent studies have shown that the global prevalence of HCV is estimated to be 1% in 2015, corresponding to 71.1 million individuals with chronic HCV infection [2,3]. The disease burden of HCV infection is due to progression of chronic liver disease, which can lead to cirrhosis, liver failure, hepatocellular carcinoma (HCC), and death. Globally, 27% of all cases of cirrhosis and 25% of all HCC is attributable to HCV infection [4].

Source: Journal of Hepatology - August 8, 2018 Category: Gastroenterology Authors: Christoph Sarrazin, Curtis L. Cooper, Michael P. Manns, K. Rajender Reddy, Kris V. Kowdley, Stuart K Roberts, Hadas Dvory-Sobol, Evguenia Svarovskia, Ross Martin, Gregory Camus, Brian P. Doehle, Luisa M. Stamm, Robert H. Hyland, Diana M. Brainard, Hongmei Source Type: research